In patients with class 2 uveal melanoma tumors, predicted metastasis-free survival by a gene expression profile test was shown to be worse than that observed in a cohort study and worse than that reported in the literature.
The DecisionDx-UM (Castle Biosciences) is a commercially available prognostication test offered by several institutions to patients with uveal melanoma as part of their management plan. Based on this test, tumors are classified as low risk (class 1A), intermediate risk (class 1B) or high risk (class 2). Predicted survival reported as percent metastasis free (Read more...)